Welcome to our dedicated page for AIM ImmunoTech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AIM ImmunoTech Inc. (AIMI/AIM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a smaller reporting biotechnology issuer focused on immuno-pharma therapeutics. AIM ImmunoTech files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements on Schedule 14A and other forms that document its financial condition, governance decisions and material events.
For investors tracking AIM ImmunoTech’s development-stage biotechnology business, the company’s periodic reports are central. The Form 10-K and Form 10-Q filings describe its status as a smaller reporting company, summarize its focus on therapeutics for cancers, immune disorders and viral diseases, and provide financial statements that reflect revenues and net losses consistent with a research-focused enterprise. A Form 12b-25 (Notification of Late Filing) for the quarter ended September 30, 2025 explains delays in completing the required review, outlines the expectation to file within the permitted extension period and describes anticipated changes in revenues, net loss and loss per share compared to prior-year periods.
AIM ImmunoTech also uses Form 8-K to report material events. Examples include furnishing a corporate presentation under Regulation FD, disclosing NYSE American notices of noncompliance with minimum stockholders’ equity requirements and the acceptance of a plan to regain compliance, and filing its Certificate of Incorporation as amended and restated as an exhibit. These current reports help investors understand exchange listing issues, governance documents and other significant developments beyond routine financial reporting.
Proxy statements on Schedule 14A, such as the definitive proxy for the 2025 Annual Meeting of Stockholders, provide detail on board elections, advisory votes on executive compensation, auditor ratification and the company’s use of scaled disclosure obligations as a smaller reporting company. Voting results for proposals, reported via Form 8-K, show how stockholders have voted on directors, compensation matters and the frequency of advisory votes.
On Stock Titan, AIM ImmunoTech’s filings are updated as they appear on EDGAR, and AI-powered tools summarize key points from lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements. This helps users quickly identify information on topics such as financial performance trends, exchange compliance, governance decisions and material agreements, while still allowing access to the full original filings for detailed review. Form 4 insider transaction data, when filed, can also be monitored alongside these core disclosures to give a fuller picture of corporate activity.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. entered into agreements for a registered direct stock offering and a concurrent private placement of warrants. The company is selling 7,519,351 shares of common stock at $0.325 per share, for expected gross proceeds of approximately $2.4 million before expenses.
The concurrent private placement includes Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share, potentially adding about $4.9 million in gross proceeds if fully exercised for cash. AIM expects to have at least $6.0 million in stockholders' equity upon closing.
Ladenburg Thalmann is acting as placement agent, receiving an 8.0% cash fee, a 0.75% management fee on aggregate gross proceeds, reimbursement of expenses, and 451,161 Placement Agent Warrants with a $0.40625 exercise price. The offerings are expected to close on or about May 21, 2026, subject to customary conditions.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.
AIM ImmunoTech Inc. extended the maturity of its promissory note with Streeterville Capital, LLC to June 30, 2027, improving near-term debt obligations. The note’s outstanding balance following a $10,000 extension fee is about $1.68 million.
The company also reported stockholder equity of approximately $2.1 million as of March 31, 2026, a swing of roughly $11.9 million from a stockholder deficit of about $9.8 million as of December 31, 2025. AIM links this stronger equity position and the note extension to supporting its pancreatic cancer development program and other strategic initiatives.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech reported a first-quarter 2026 net loss of $3.0M on minimal revenues of $22K, reflecting its development-stage status. Operating expenses fell sharply to $2.2M from $3.6M a year earlier, mainly from lower research and general and administrative costs.
Cash and cash equivalents increased to $5.8M at March 31, 2026 from $3.0M at year-end 2025, helped by equity sales, warrant exercises and a $1.8M Series G preferred stock rights offering. Stockholders’ equity improved from a deficit of $(9.8)M to positive equity of $2.1M, aided by an $8.7M reclassification of Class E and F warrants from liability to equity.
The company still faces significant risk: management notes substantial doubt about its ability to continue as a going concern, with working capital constraints, ongoing losses and stockholders’ equity of $2.1M versus the $6M minimum required to maintain NYSE American listing. It relies on additional financings, including Streeterville promissory notes and at-the-market equity sales, while advancing Ampligen for late-stage pancreatic cancer through the DURIPANC Phase 2 study and planning a Phase 3 trial with Thermo Fisher Scientific’s PPD unit.
AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.
The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.
AIM ImmunoTech Inc. filed a report highlighting a Virtual Investor Key Opinion Leader segment focused on Ampligen (rintatolimod) for late-stage pancreatic cancer. The segment features Professor Casper H.J. van Eijck of Erasmus Medical Center and AIM’s CEO discussing Ampligen’s mechanism, clinical data and development strategy.
The company recaps prior Named Patient Program results suggesting longer progression-free survival and overall survival versus historical controls, and notes ongoing Phase 2 DURIPANC trial work with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The press release and video segment are furnished, not filed, and include customary forward-looking statement cautions.
AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.
In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.
The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.
AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.
In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.
The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.